Month: August 2020

NEWTOWN, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that on August 3, 2020 it received a letter from The Nasdaq Stock Market LLC stating that the Company had regained compliance with the minimum bid price requirement of the Nasdaq Listing Rule 5550(a)(2) because the Company’s common stock had a minimum closing price of at least $1.00 per share for a minimum ten consecutive business days.About Onconova Therapeutics, Inc.Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel drugs to treat cancer, with an initial focus on myelodysplastic syndromes (MDS)....

HSINCHU,TAIWAN, Aug. 04, 2020 (GLOBE NEWSWIRE) — Picocom has selected the AndesCoreÔ N25F RISC-V 32-bit core integrated with the AE350 peripherals platform for its forthcoming 5G small cell distributed unit (DU) System-on-Chip (SoC). Picocom is a 5G open RAN baseband semiconductor company with vast experience in the field of small cells. Its chosen partner, Andes Technology, is a leading supplier of high-performance, low-power compact 32/64-bit RISC-V CPU cores and the Founding Premier member of the RISC-V International Association.Picocom is championing ‘open RAN’ – the disaggregation of 5G radio access networks (RAN), which will open up the supply chain enabling new vendors to enter the market and compete. With Andes performance efficient cores, Picocom’s DU baseband offload SoC will deliver the needed flexibility,...

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody® therapeutic technology platform, announced today that Sean McCarthy, D.Phil., president, chief executive officer and chairman, will participate in the 2020 Wedbush PacGrow Virtual Healthcare Conference.A live audio webcast of the presentation will be available through the Events and Presentations page of CytomX’s website at www.CytomX.com. An archived replay will be available for 90 days following the event.About CytomX TherapeuticsCytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We...

Festi birtir uppgjör sitt fyrir 2. ársfjórðung 2020 eftir lokun markaða fimmtudaginn 6. ágúst næstkomandi.Opinn kynningarfundur verður haldinn föstudaginn 7. ágúst 2020 í höfuðstöðvum félagsins að Dalvegi 10 – 14 Kópavogi 3. hæð. Eggert Kristófersson forstjóri Festi mun kynna afkomu samstæðunnar og svara spurningum.Fundurinn hefst kl. 08:30. Boðið verður upp á morgunverð frá kl. 08:00. Kynningarefni vegna fundarins verður hægt að nálgast að honum loknum á heimasíðu Festi: www.festi.is/fjarfestatengsl

Med henvisning til LIF § 75, stk. 1, skal det hermed oplyses, at den indre værdi i perioden den 3. august kl. 10.03 – 4. august d.å. kl. 11.51 har været 0,9 pct. for høj i afdeling Europæiske Ejendomsaktier (DK0061133899).Foreningens prisstiller og distributør er blevet underrettet.Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til undertegnede på telefon 38 14 66 00.Med venlig hilsenInvest Administration A/S

– COVID-19 Clinical Development Program Topline Data Readout of Multi-Center Study Expected in Q4 2020 –– Plan to Initiate New Clinical Study in Ulcerative Colitis in Q3 2020 – LEXINGTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) — Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced financial results for the second quarter 2020 and provided a corporate update. “We have made several important advancements across critical areas of the business, including initiating two clinical studies in our COVID-19 program and strengthening our financial foundation by extending our cash runway into the second half of 2021,” said Michael Bonney, Executive Chair of Kaleido. “We anticipate...